Literatur
Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, Marchiori A, Sabbion P, Prins MH, Noventa F, Girolami A (2002) Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100(10):3484–3488
Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, Wong SL, Balaban EP, Flowers CR, Francis CW, Gates LE, Kakkar AK, Levine MN, Liebman HA, Tempero MA, Lyman GH, Falanga A (2020) Venous Thromboembolism prophylaxis and treatment in patients with cancer: aSCO clinical practice guideline update. J Clin Oncol 38(5):496–520
Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, Grosso MA, Kakkar AK, Kovacs MJ, Mercuri MF, Meyer G, Segers A, Shi M, Wang TF, Yeo E, Zhang G, Zwicker JI, Weitz JI, Büller HR, Hokusai VTE Cancer Investigators (2018) Edoxaban for the treatment of cancer-associated venous Thromboembolism. N Engl J Med 378(7):615–624
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
A.G. Barutcu, H. Alakus und C. Bruns geben an, dass kein Interessenkonflikt besteht.
Rights and permissions
About this article
Cite this article
Barutcu, A.G., Alakus, H. & Bruns, C. Apixaban zur Behandlung venöser Thrombembolien bei Krebspatienten. Onkologe 26, 758–759 (2020). https://doi.org/10.1007/s00761-020-00783-w
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00761-020-00783-w